Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

Prior treatment

• Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or are expected to receive these agents during the study.
• Have previous or current receipt of humanized or human monoclonal antibody (mAbs), or polyclonal immunoglobulin.
• Have previous history of an antidrug antibodies response to a therapeutic agent.
• Have previous receipt of an HIV vaccine.
• Received any vaccine or immunomodulatory medication within 4 weeks prior to screening.

Other illness

• Have current Class C acquired immunodeficiency syndrome (AIDS)-defining condition.
• Have any serious or active medical or psychiatric illness that would interfere with participants treatment, assessment, or compliance with the protocol.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Lab values

• Positive serum pregnancy test.
• Females with coinfection and/or immunosuppression as described below:
  • Autoimmune disease requiring ongoing immunosuppression
  • Evidence of chronic hepatitis B virus (HBV) infection
  • Evidence of current hepatitis C virus (HCV) infection
  • Documented history of pre-ART CD4+ T cell count nadir \< 200 cells/μL
  • History of opportunistic illness indicative of Stage 3 HIV
  • Acute febrile illness within 4 weeks prior to the first dose
• Have a history of any of the following:
  • Significant serious skin disease
  • Significant drug sensitivity or drug allergy
  • Known hypersensitivity to the study drugs, metabolites, or formulation excipients
  • Previous or current history of bleeding disorder, platelet disorder including unexplained acute or chronic thrombocytopenia
  • Autoimmune diseases including type 1 diabetes mellitus

Other

• Have poor venous access that limits phlebotomy.
• Nursing participants.
• Have current alcohol or substance abuse judged by the investigator to potentially interfere with individual's compliance or individual's safety.

• Age ≥ 18 years
• Females recruited from the Females Rising through Education, Support, and Health (FRESH) acute human immunodeficiency virus (HIV) infection cohort.
• Plasma human immunodeficiency -1 (HIV-1) ribonucleic acid (RNA) levels \< 50 copies/mL at the screening visit.
• On antiretroviral (ART) regimen for ≥ 12 consecutive months prior to the screening visit.
• Have all the following laboratory values at the screening visit:
  • Hemoglobin ≥ 10.0 g/dL
  • White blood cells ≥ 2500 cells/μL
  • Platelets ≥ 125,000/mL
  • Absolute neutrophil counts ≥ 1000 cells/μL
  • Cluster of differentiation (CD)4+ T cell count ≥ 500 cells/μL
  • Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin ≤ 2 × upper limit of normal (ULN)
  • Creatinine clearance ≥ 60 mL/min
• Women of childbearing potential to have documentation of agreement to follow study contraceptive requirements.
• Documented plasma HIV-1 RNA \< 50 copies/mL for 12 consecutive months prior to the screening visit.
• In the judgment of the investigator, be in good general health.
• Documented history of viral sensitivity to VRC07-523LS or CAP256V2LS at the screening visit.